Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFC-Containing Albuterol Phase-Out Review To Begin January 2003

Executive Summary

FDA will begin the phase-out process for CFC-containing albuterol and beclomethasone products after Jan. 20, 2003, when its final rule on ozone-depleting substances goes into effect

You may also be interested in...



Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access

Increases in cost of albuterol inhalers due to the transition from chlorofluorocarbons to non-ozone depleting substances could affect patient access, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested

Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access

Increases in cost of albuterol inhalers due to the transition from chlorofluorocarbons to non-ozone depleting substances could affect patient access, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested

Albuterol CFC Phase-Out Date Needed Now For HFA Ramp Up, Firms Says

A lack of a definitive date for the phase-out of chlorofluorocarbon propelled albuterol metered dose inhalers could delay ramp up of production of inhalers that use non ozone depleting substances, manufacturers suggested at the June 10 meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel